Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Non-Current Assets (2019 - 2025)

Silence Therapeutics (SLN) has disclosed Non-Current Assets for 7 consecutive years, with $12.8 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 16.27% to $12.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.8 million through Dec 2025, down 16.27% year-over-year, with the annual reading at $12.8 million for FY2025, 16.27% down from the prior year.
  • Non-Current Assets hit $12.8 million in Q4 2025 for Silence Therapeutics, down from $13.2 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $16.7 million in Q2 2025 to a low of $12.7 million in Q4 2022.
  • Historically, Non-Current Assets has averaged $14.4 million across 5 years, with a median of $14.3 million in 2021.
  • Biggest five-year swings in Non-Current Assets: increased 25.26% in 2023 and later fell 16.27% in 2025.
  • Year by year, Non-Current Assets stood at $13.3 million in 2021, then dropped by 4.58% to $12.7 million in 2022, then grew by 25.26% to $15.9 million in 2023, then decreased by 3.9% to $15.3 million in 2024, then dropped by 16.27% to $12.8 million in 2025.
  • Business Quant data shows Non-Current Assets for SLN at $12.8 million in Q4 2025, $13.2 million in Q3 2025, and $16.7 million in Q2 2025.